#USA #Pulsed Field Ablation #Del Medtech #Steven Mickelsen #Cardiff by the Sea

Introduction

Dr. Steven Mickelsen, a renowned electrophysiologist and pioneering force behind pulsed field ablation (PFA), recently announced the inception of his new venture, Del Medtech Inc. This seed-stage medical device company is set to embark on a transformative journey aimed at expanding the applications of PFA technology beyond its traditional cardiac usage.

Company Vision

Del Medtech is poised to redefine minimally invasive ablation practices, tackling critical unmet needs within diverse therapeutic areas. Dr. Mickelsen emphasizes the aspiration of establishing a global standard in tissue ablation that enhances patient outcomes. "Our vision is to set a new standard in minimally invasive ablation and expand PFA's impact beyond the heart," he stated confidently during the announcement.

Innovations in Ablation Technology

Focusing on the development of single-use ablation devices, Del Medtech targets multiple domains, including gastroenterology (GI), ear, nose and throat (ENT) medicine, men’s and women’s health, and oncology. The estimated market potential for these areas ranges from $1.4 billion to a staggering $7.4 billion, with projected growth rates spanning between 9% and 13%. Dr. Mickelsen recognizes the significant opportunities that lie in these fields, stating, “Our focus on these segments aims to improve efficiency and patient care with our innovative devices.”

Historical Context

In the past five years, the advent of PFA has refashioned catheter ablation techniques substantially. Understanding this transformative impact, Dr. Mickelsen plans to leverage these insights to tackle persistent challenges that have remained outside the heart, venturing into new and innovative applications of this technology.

Upcoming Presentation

To further elucidate Del Medtech's objectives and innovative approaches, Dr. Mickelsen is scheduled to present at the upcoming LSI Emerging Medtech Summit in London on September 8. This prestigious gathering will showcase global leaders dedicated to healthcare innovation, offering an ideal platform for Dr. Mickelsen to share his vision for the future of medical technology.

"We are entering a period of rapid acceleration in ablative therapies, akin to the rise of PFA within electrophysiology," Dr. Mickelsen remarked. His enthusiasm for the company's direction is palpable, as he encourages prospective investors and partners to join Del Medtech in shaping the future landscape of ablation technologies.

Conclusion

Founded in 2024 by the driven and innovative Dr. Steven Mickelsen, Del Medtech stands ready to challenge traditional healthcare approaches. By venturing into the realms of gastroenterology, ENT, and oncology, the company is not only about introducing new medical devices but is committed to being at the vanguard of a healthcare revolution. Investors and partners looking to contribute to this exciting and transformative journey in ablation technology will find a welcoming environment within Del Medtech. As the medical community looks ahead, the significance of innovative ablation therapies cannot be understated, highlighting the importance of initiatives like those from Del Medtech.

Call to Action

Keep an eye on Del Medtech as it carves a niche in the rapidly evolving field of medical technology, ensuring accessible, effective, and innovative healthcare solutions for all. The future is indeed bright with pioneering companies such as Del Medtech leading the way.